Truist Securities Maintains Hold on Integra Lifesciences, Lowers Price Target to $21
Portfolio Pulse from Benzinga Newsdesk
Truist Securities has maintained a Hold rating on Integra Lifesciences while lowering the price target from $26 to $21.
October 14, 2024 | 2:13 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Truist Securities has maintained a Hold rating on Integra Lifesciences and reduced the price target from $26 to $21, indicating a less optimistic outlook.
The reduction in price target from $26 to $21 by Truist Securities suggests a less favorable view on Integra Lifesciences' future performance, which could lead to a negative short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100